The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?

José R Blanco; Antonio Rivero-Juárez

doi:10.1080/14787210.2016.1243466

The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?

Expert Rev Anti Infect Ther. 2016 Nov;14(11):993-996. doi: 10.1080/14787210.2016.1243466.

Authors

José R Blanco¹, Antonio Rivero-Juárez²

Affiliations

¹ a Infectious Diseases Area , Hospital San Pedro, Center for Biomedical Research of La Rioja (CIBIR) , Logroño , La Rioja , Spain.
² b Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba , Universidad de Córdoba , Córdoba , Spain.

PMID: 27686837
DOI: 10.1080/14787210.2016.1243466

No abstract available

Keywords: Direct acting antivirals hepatitis c; HCC development; hepatocellular carcinoma; interferon-free regimen; sustained virological response.

Publication types

Editorial

MeSH terms

Antiviral Agents / therapeutic use*
Carcinoma, Hepatocellular / epidemiology*
Carcinoma, Hepatocellular / etiology
Hepatitis C, Chronic / complications
Hepatitis C, Chronic / drug therapy*
Humans
Liver Cirrhosis / epidemiology
Liver Cirrhosis / etiology
Liver Neoplasms / epidemiology*
Liver Neoplasms / etiology
Risk
Sustained Virologic Response

Substances

Antiviral Agents